廣信材料(300537.SZ):暫時沒有研發 EUV 的具體計劃
格隆匯9月18日丨廣信材料(300537.SZ)在投資者關係中表示,在光刻膠及配套材料領域,公司目前還是基於 PCB 領域的基礎逐步向光伏、顯示及半導體領域發展,出於對行業及產業鏈情況、市場情況以及公司自身資金情況等整體考慮,公司目前仍然以 PCB 光刻膠及新增的光伏膠為主顯示光刻膠為輔的整體策略,並根據未來資金及市場情況考慮推進更高生產及研發投入更高的高世代半導體領域。根據公司目前經營規模、資金情況和開發規劃,暫時沒有研發 EUV 的具體計劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.